Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MLSCI 330 > Leukemias > Flashcards

Leukemias Flashcards

1
Q

causes of leukocyte neoplasms or leukemia

A

damage to HSC ( red marrow)
- radiation
- chemotherapy
- chemical and rug exposure
- viral infections (HTLV, EBV)
- oncogene mutations
- secondary to other conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

general characteristics of acute leukemia

A
  • sudden onset
  • rapid progression, esp. with no treatment
  • immature cells involved; blasts
  • all age groups
  • 6 mos life expectancy if not treated
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

general characteristics of chronic leukemia

A
  • slow, insidious onset
  • asymptomatic
  • slow progression
  • mature cells involved
  • common in adults, rare in children
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

myeloblasts vs lymphoblasts

A
  • myelo: larger, numerous nucleoli, auer rods
  • lympho: smaller, scant cytoplasm, indistinct nucleoli
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

precipitated peroxidase proteins

A

auer rods

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

type I vs type II myeloblasts

A

type I = no granules
type II = few to many azurophilic granules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

promyelocytic leukemia

A
  • very heavy granulation in promyelocytes
  • may be some blasts present but promyelocytes are predom
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

microgranular variant PL

A

butterfly nuclei
may see very fine stippling or very fine ground glass granule appearanceo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

myeloperoxidase

A

found in primary granules
stains granulocytes and monocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

sudan black

A

cellular lipids in 1ry and 2ry granules; similar reactivity to MPO/MPX
stains granulocytes and monocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

alpha-naphthyl acetate esterase stain (NSE)

A

non-specific esterase
high activty in monocytes/macs/histocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PAS

A

stains glycogen in cytoplasm
primarily stains lymphs, erythroblasts, megakaryocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

these will differentiate between myeloid and lymphoid lineage

A

MPO/MPX, Sudan Black
pos for granulocytes and moncytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

this stains monocytes reddish/brown

A

NSE
dark staining in cells that are monoblastic in lineage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

this shows block positivity

A

PAS
very strnog pos in lympphoblasts and diffuse pos rxn in erythroblasts and megs (staining is scattered around cell, not as intense)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

lymphoid lineages CD

A

2,3,4,5,7,819,20,22

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

B cell CD

A

19,20,22

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

T cell CD

A

2,3,4,5,7,8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

TdT

A

terminal deoxynucleotidyl transferase
- DNA polymerase in stem cells, early lymph cells
- seen in ALL (pos in both B and T cell)
- can be detected via monoclonal Abs through flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

karyotyping helps to…

A

diagnose
sub-classify
monitor residual disease
prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

molecular genetics to differentiate blasts

A

karyotyping at molecular level
helps to show disease progression, accurate prognosis, predict response to therapy
detection of mutations, gene arrangements using PCR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is the difference between lymphomas and leukemias

A

leukemia = PB and BM involvement
lymphoma = PB, BM, and lymph node (tumor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

how do we classify B cell and T cell leukemias

A

B cell = recurrent genetic abnormalities or NOS (no specific gene abnormalities)

T cell = no further classification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

B-cell lymphoblastic leukemia/lymphoma

A
  • small blasts: scant blue cytoplasm with condensed chromatin
  • large blasts: moderate light blue to grey cytoplasm, may have vacuolation with dispersed chromatin
  • typical = anemia, infections, fever, organomegaly, bone pain
  • WBC count variable with neutropenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

T- cell lymphoblastic leukemia/lymphoma

A
  • cytogenetic abnormalities common
  • blasts indistinguishable from B cell blasts
  • typical acute anemia symptoms
  • WBC count increased
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

how to know if ALL is B cell or T cell

A

cytochemical staining will only tell us it is ALL… so need flow cytometry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

types of acute myeloid leukemia

A
  • APL with recurrent genetic abnormalities (APL w PML-RARA)
  • AML with myelodysplasia
  • therapy-related myeloid neoplasms
  • AMS, NOS
  • myeloid sarcoma
  • myeloid proliferation related to down syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

CBC of chronic leukemia

A
  • mature cells in BM; increased M:E
  • WBC increased
  • N/N anemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

PBS = mature cell morphologies with left shift

A

chronic leukemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

describe CLL

A
  • mature b-cell neoplasm
  • immunologically incompetent lymphs
    > altered humoral immunity
    > hypogammaglobulinemia
    > increased infections = complications, death
    > may lead to autoimmune disorders (hemolytic anemia, thrombocytopenia (ITP))
    > malignant b cells do not progress to normal plasma cells
    > bystander b cells produce autoantibodies (not leukemic clones)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

WBCs in CLL

A

high (20-250)
lymphocytosis
neutropenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

RBCs in CLL

A

decreased
N/N anemia (unless AIHA = retics and spherocytosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

PLTs in CLL

A

normal until advanced = decrease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

CLL PBS

A

mature lymphs
pro-lymphs
smudge cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

CLL BM

A

hypercellular
increase in small lymphoid cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Flow for CLL

A

CD19+, 20+. 22+
CD5+ (usually only T cells nut seen in 90% of CLL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

this is TRAP stain pos

A

hairy cell leukemia
- lymphs pos for acid phosphatase and resistant tartrate (other cells neg after adding tartrate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

hairy cel leukemia immunophenotype

A

CD123+ (b cell markers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

hairy cell leukemia diagnosis

A
  • TRAP pos
  • CD123+
  • trephine biopsy to show increase marrow fibrosis + hairy cells
  • Annexin A1 positive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

plasma cell neoplasms

A
  • either increase in complete or incomplete immunoglobulins
  • can lead to hypergammaglobulinemia
    > monoclonal = single clone, increase in single type of immunoglobulin
    > polyclonal = different immunoglobulin, broad increase in gamma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

monoclonal gammopathies

A

increased abnormal Igs (para-protein or M-protein)
complete one of IgA,IgG,IgE,IgD,IgM and excess free light chains

42
Q

MGUS can turn into…

A

Multiple myeloma if class switch to IgG, IgA
Waldenstrom’s macroglobulinemia if switched to IgM

43
Q

properties of the M-protein

A

cryo-protein
pyroglobulin (precipitates when heated; Bence-Jones)
cold-agg due to cryoglobulin
hyper-viscosity (increased protein in blood)
interference in coag = fibrin formation interference, coat PLT and coag factors (can’t participate in coag)
amyloidosis (excess proteins precipitate out into tissue)
attract basic dyes so blue background staining on PBS

44
Q

MGUS

A
  • M-protein in blood but <30 g/L
  • BM plasma cells <10%
  • no CRAB
  • may not progress to malignancy, monoclonal spike
  • no pt symptoms
45
Q

plasma cell myeloma

A
  • abnormal proliferation of plasma cells and b cells in BM
  • osteolytic destruction of bone
    > bone pain, osteoporosis, fractures
    > lesions on X-ray
    > decrease height
    > release of calcium due to bone destruction = hypercalcemia
  • tubular damage form light chain proteinuria
  • anemia (EPO loss, HSC replacement
    (CRAB)
46
Q

PBS and CBC of plasma cell myeloma

A
  • N/N anemia
  • decreased retics
  • plts/wbcs normal to decreased
  • occasional plasma cell
  • rouleaux
  • neutropenia
47
Q

BM of plasma cel myeloma

A

plasma cells (flame)
hypercellularity

48
Q

ESR and flow of plasma cell myeloma

A
  • ESR increased
  • flow = CD8,56,79,138 pos
    CD19 neg
49
Q

chemistry of plasma cell myeloma

A

increased protein in serum and urine
increased calcium

50
Q

protein electrophoresis of plasma cell myeloma

A
  • increased monoclonal
  • IFE = bence-jones (light chains)
51
Q

T or F. heavy chains cannot be cleared by the kidney

A

T! only light chains are found in urine

52
Q

how to differentiate PCM vs plasmacytosis

A

plasmacytosis = no CRAB, no gamma peak

53
Q

Waldenstrom’smacroglobulinemia

A
  • type of non-Hodgkin lymphoma (lymphoplasmacytic lymphoma)
  • monoclonal peak, IgM
  • b cells start to mimic plasma cells
  • cells infiltrate BM, spleen, liver
  • anemia, thrombocytopenia, neutropenia
  • decreased normal IgG
  • no CRAB
54
Q

CBC/PBS of WM

A

N/N anemia
rouleaux
neutropenia

55
Q

BM of WM

A

plasmacytoid lymph
no CRAB

56
Q

ESR and flow of WM

A

increased ESR
CD19, 20, 24 pos
light chain restriction (only kappa or only lambda)

57
Q

myeloproliferative neoplasms

A
  • can progress to acute leukemia
  • unregulated proliferation of myeloid HSCs
  • affect middle-aged to older adults
  • CML, PV, ET, PMF
58
Q

features of MPNs

A
  • hypercellular BM (increased grans and megs with abnormal morph)
  • increased gran in PBS, normal morph
  • initial increase of RBC, PLT (dysfunctional) followed by marrow fibrosis
  • splenomegaly and hepatomegaly common
  • low onset
  • tyrosine kinase genes abnormalities
59
Q

abnormal activation of tyrosine kinases

A

leads to uncontrolled and unregulated cell proliferation (i.e. cells won’t know when to die)

60
Q

CML

A
  • Philadelphia chromosome pos (BCR/ABL gene fusion)
  • increased + uncontrolled proliferation of granulocytes
  • ACQUIRED
61
Q

Philadelphia chromosome

A
  • translocation between long arms of chr 9 and 22 (reciprocal)
  • chr 9 longer, chr 22 shorter
  • only found in leukemia cells
  • leads to formation of the BCR/ABL gene -> increased tyrosine activity
62
Q

T or F. The Philadelphia chromosome is only resent in HS tissues such as RBCs, neuts, PLTs, basophils, monocytes…

A

T! not present in lymphs or non-hem stem cells

63
Q

CBC/PBS of CML

A
  • N/N anemia
  • retics normal or decreased
  • PLT dysfunction
  • WBC increased >25
  • left shift (increase in myeloids)
  • blasts <2%
  • nRBC
  • basophilia, neutrophilia, etc.
64
Q

BM of CML

A
  • hypercelular (increased M:E)
  • normoblasts decreased
  • blasts <5%
  • megakaryocytes normal to increased; clusters
  • fibrosis with disease progression
65
Q

LAP stain CML

A

normal or decrease

66
Q

how to see BCR/ABL translocation

A

southern blot
PCR

67
Q

phases of CML

A
  • chronic: stable and responsive to therapy
  • accelerated: 3-5 yrs after onset; symptoms worsen; blasts 10-19%; less responsive to therapy
  • blast: >20% in PBS or BM => AML
68
Q

drug for CML

A

Gleevec

69
Q

polycythemia vera

A

panmyelosis (primarily erythroid precursors)
JAK2 V617F mutation
> AA substitution => continuous activation of JAK2 kinase
> continuous EPO activation even though EPO absent

70
Q

JAK2 V617F mutation

A

bypasses EPO
EPO independent proliferation of RBC
EPO levels decreased or absent

71
Q

causes of JAK2 V617F mutation

A

radiation or toxin exposure

72
Q

PV patient symptoms

A
  • hyperviscosity -> thrombosis
  • increased PLT -> bleeding
  • headaches, nosebleeds, stroke, angina, MI, visual disturbances, itching (increased basos and histamine)
  • patients can transform into spent phase - anemia and marrow fibrosis and splenomegaly bc BM so overworked &exhausted
  • can transform into blast phase (acute leukemia; 15%)
73
Q

CBC/PBS of PV

A
  • Hb >165 g/L
  • increased Ht and RBC
  • N/ to M/H anemia
  • retic N
  • WBC/PLT increased; may see left shift (but normal morph)
74
Q

BM of PV

A

hypercellular (M:E normal)
cell morph = normal
iron stores decrease/absent
megs increase and atypical
disease progression => fibrosis

75
Q

this demonstrates PV’s EP-indepdent erythropoiesis

A

endogenous erythroid culture
- harvest malignant HSC tissue and give them everyting needed to grow but dont give EPO; pts with PV will still make HSCs and will still differentiate

76
Q

major diagnosing criteria for PV

A
  • increased Hb (>165F; >185M)
  • JAK2 mutation
77
Q

PV treatment

A

phleb (may make pts more iron def)
myelosuppressive agents (can increase risks of transforming to leukemia)

78
Q

secondary PV

A
  • caused by tissue hypoxia (high altitudes, cardiac diseases, pulmonary disorders, obesity, increased methem in smokers, Hb barts (abnormal Hb and O2 affinity)
  • inappropriate EPO increases (kidney lesions/tumors, androgen or EPO abuse, chemical exposure (cobalt))
79
Q

CBC of secondary PV

A

Hb/Hct increase
WBC/PLT normal

80
Q

T or F. The LAP of secondary PV is decreased

A

F! it is normal

81
Q

BM of secondary PV

A

erythroid hyperplasia

82
Q

tissue hypoxia causes EPO to

A

increase

83
Q

relative PV

A
  • caused by dehydration (decrease inplasma vol) or smoking
  • CBCD = Hb and Ht increased; WBC/PLT normal
  • BM = normal; EPO normal
  • plasma layer decreased by a lot so looks like lot of RBCs but this is false
84
Q

essential thrombocytopenia

A
  • megs and PLTs affected
  • can convert to AML
  • lots of genetic mutations associated
85
Q

ET patient symptoms

A

mild bleeding probs (nosebleeds, easy bruising)
thrombosis
headaches
dizziness
blurred vision
abnormal functioning PLT
asymptomatic often

86
Q

CBC/PBS of ET

A

increase in PLTs (600 to 1000)
giant plts, clumps, agranular
megakaryocytic fragments
N/N to M/H anemia

87
Q

BM of ET

A

increase in megs and larger, clusters, and hyperlobulated
normal to hypercellular

88
Q

PLT testing for ET

A

adhesion and agglutination is abnormal

89
Q

primary myelofibrosis

A

overproduction of HSC and fibroblasts
> increased grans and megs in BM

reactive fibrosis and collagen increase 2ry to increased release of fibroblastic growth factors secreted by malignant or neoplastic megs

lots of genetic muations associated

90
Q

PM phases

A

initial or pre-fibrotic: hypercell BM and minimal reticulin buildup

fibrotic: increased retic and collagen deposit in BM, organomegaly (spleen and liver), extramed hematopoiesis (teardrops)

can transform to AML

91
Q

PM lab tests for initial phase

A

increase in WBCs and PLTs, N/N anemia
hypercell Bm and lots of megs and grans

92
Q

PM lab tests for fibrotic phase

A

CBCD/PBS = poikilocytosis (tears, elliptos, nRBCs), myeloid precursors and blasts (leukoerythroblastic)
BM = decrease WBCs and PLTs (abnormal & large)

93
Q

diagnosing PM stain

A

reticulin stain after trephine biopsy

94
Q

micromegakaryocytes look like

A

lymphs

95
Q

clonal disorders with progressive cytopenia in PB

A

myelodysplastic syndromes

96
Q

MDS

A
  • dysplastic and ineffective production of blood components
  • early = cytopenia and increased apoptosis
  • late = apoptosis decreased, increased malignant and neoplastic cell survival, progression towards leukemia
  • abnormal cell function
97
Q

how does MDs develop

A
  • exposure to chemicals (benzene)
  • smoking
  • Hx of hematopoietic neoplasms in family
  • environmental toxin exposure
  • may develop secondary to therapy
98
Q

dyserythropoiesis

A
  • refractory anemia from treatment
  • low retics
  • PBS = N/N anemia, macro, M/H, oval macro, tears, schistos, acanthos, spheros, BS, nRBC, HJ bodies
  • BM = meg changes, large multi-nuclear normoblasts, nuclear fragments, karyorrhexis, ringed sideroblasts
99
Q

dysmyelopoiesis

A

PBS = neutropenia, moncytosis, blasts <20%, agranular, pseudo-PH

BM = abnormal grans, N:C asynchrony, megaloblastic changes, abnormal staining of cells

100
Q

dysmegakaryopoiesis

A

PBS = decreased PLTs, giant PLTs, agranular

BM = abnormal megs, large cells with meg changes, nuclei detached from one another, agranular PLTs, multi-lobed megs, abnormal cells in sheets or clusters

MLSCI 330 (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions